Shares of Tabula Rasa Healthcare Inc. (NASDAQ:TRHC) have been given an average rating of “Buy” by the seven brokerages that are currently covering the company, MarketBeat reports. One investment analyst has rated the stock with a hold rating and six have issued a buy rating on the company. The average twelve-month price target among brokerages that have covered the stock in the last year is $18.20.
TRHC has been the subject of a number of recent analyst reports. Zacks Investment Research upgraded Tabula Rasa Healthcare from a “sell” rating to a “hold” rating in a report on Tuesday, May 16th. Stifel Nicolaus reissued a “buy” rating and issued a $16.00 target price on shares of Tabula Rasa Healthcare in a research note on Friday, July 14th. Chardan Capital began coverage on Tabula Rasa Healthcare in a research note on Monday, July 10th. They issued a “buy” rating and a $19.50 target price on the stock. Robert W. Baird increased their target price on Tabula Rasa Healthcare from $17.00 to $18.00 and gave the stock an “outperform” rating in a research note on Tuesday. Finally, UBS AG reissued a “buy” rating and issued a $17.00 target price (down from $18.00) on shares of Tabula Rasa Healthcare in a research note on Thursday, May 25th.
In related news, Director Gordon Tunstall sold 22,759 shares of the firm’s stock in a transaction that occurred on Monday, June 12th. The stock was sold at an average price of $13.76, for a total transaction of $313,163.84. Following the completion of the sale, the director now directly owns 5,565 shares of the company’s stock, valued at approximately $76,574.40. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Orsula V. Knowlton sold 8,000 shares of the firm’s stock in a transaction that occurred on Wednesday, May 17th. The stock was sold at an average price of $11.94, for a total value of $95,520.00. Following the sale, the insider now directly owns 919,407 shares of the company’s stock, valued at $10,977,719.58. The disclosure for this sale can be found here. In the last quarter, insiders sold 46,759 shares of company stock valued at $634,444. Company insiders own 45.80% of the company’s stock.
Tabula Rasa Healthcare (NASDAQ TRHC) traded down 1.44% during mid-day trading on Friday, reaching $17.17. 53,416 shares of the company’s stock traded hands. The company has a 50 day moving average price of $14.71 and a 200-day moving average price of $14.02. Tabula Rasa Healthcare has a 12 month low of $10.39 and a 12 month high of $17.88. The stock’s market cap is $295.63 million.
Tabula Rasa Healthcare (NASDAQ:TRHC) last announced its quarterly earnings data on Monday, August 7th. The company reported $0.06 earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.06. Tabula Rasa Healthcare had a negative return on equity of 12.06% and a negative net margin of 10.27%. The firm had revenue of $29.70 million during the quarter, compared to the consensus estimate of $27.84 million. The business’s revenue was up 32.6% compared to the same quarter last year. On average, analysts anticipate that Tabula Rasa Healthcare will post $0.41 EPS for the current year.
About Tabula Rasa Healthcare
Tabula Rasa HealthCare, Inc (Tabula Rasa), formerly CareKinesis, Inc, is a provider of patient-specific, data-driven technology and solutions that enable healthcare organizations to optimize medication regimens to improve patient outcomes, reduce hospitalizations and manage risk. The Company delivers its solutions through a suite of technology-enabled products and services for medication risk management, which includes bundled prescription fulfillment and adherence packaging services for client populations with complex prescription needs.
What are top analysts saying about Tabula Rasa Healthcare Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Tabula Rasa Healthcare Inc. and related companies.